Company intelligence / Profile preview

Translate Bio

Lexington, Massachusetts, United Statesdnb.com ↗

Ownership: Private
Development stage: Phase 2

Overview

In March 2021, their experimental cystic fibrosis drug failed to improve lung function in a small trial. As of September 2021, they had a COVID-19 vaccine in Phase 1/2 clinical trial with results expected by the end of September 2021.

Therapeutic areas: PulmonologyMetabolic Disorders
Modalities: mRNA therapeutics
Industry: Biotech

Drug pipeline

3 assets

pomulmeran

Phase 2

Indications: Cystic fibrosis

2 more assets in the full pipeline.

Request access →

Partnerships

Sanofi (since 2018, before acquisition)

Beyond the preview

Go deeper on Translate Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Translate Bio.

Explore the full profile